Repligen buys BioLife for $1.5bn in cell therapy push
Repligen is acquiring BioLife Solutions for $1.5 billion to capture a larger share of the recovering cell therapy market, marking the latest in a wave of bioprocessing mergers.
Repligen Corp agreed on Wednesday to acquire BioLife Solutions in a cash-and-stock deal valued at approximately $1.5 billion. Under the terms, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share they own. This structure values the cell therapy tools supplier at $31 per share, representing a 6.2% premium to BioLife’s last closing price.
The acquisition provides Repligen with critical technology used to preserve cells throughout the manufacturing supply chain. It also adds BioLife’s portfolio of cell-processing instruments and a high-margin consumables business. For Repligen, a provider of drugmaking equipment, these assets directly expand its footprint in the fast-growing cell therapy market.
For market participants, the transaction is the latest evidence that the bioprocessing sector is experiencing a tangible recovery. Biotech and pharmaceutical companies significantly curtailed research spending and allowed customer inventories to deplete in recent years. However, larger peer Danaher signaled on Tuesday that demand for bioprocessing products and biologic manufacturing equipment is finally rebounding.
This rebound is accelerating merger and acquisition activity among industrial suppliers. Just last month, German drugmaker Merck KGaA announced an $11.3 billion deal to purchase Bio-Techne. Repligen’s takeover of BioLife reinforces a clear pattern: large life sciences conglomerates are aggressively acquiring companies that manufacture tools for complex drug development.
From a financial perspective, Repligen anticipates the BioLife acquisition will immediately increase its earnings. The company projects at least $20 million in cost savings during the first full year following the deal's closure. These savings will be driven by the elimination of overlapping costs and broader operational efficiencies across the combined entity.
The boards of both companies have unanimously approved the transaction, which requires regulatory clearances and shareholder votes. Execution, however, will take time, as the deal is slated to close in the fourth quarter of 2026. BioLife had already been preparing for such an outcome, having sold its evo cold-chain logistics unit for $25.5 million in October 2025 to narrow its focus entirely on cell and gene therapy products.
